# Early phase 1 recurrence trials recruiting: 31 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials in early phase 1 for recurrence that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 recurrence trials: 31 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/recurrence

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 31
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 19, 2026 | NCT07774533 | 68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma | Peking University First Hospital | Early phase 1 | Recruiting | Osteosarcoma, Osteosarcoma, Recurrent, Refractory | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774533) |
| August 18, 2026 | NCT07771803 | A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) | Sponsor not shown (see the record) | Early phase 1 | Recruiting | AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771803) |
| July 10, 2026 | NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia | Zhujiang Hospital | Early phase 1 | Not yet recruiting | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07696481) |
| July 10, 2026 | NCT07695012 | CAR-T Cell Therapy for ALL | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Relapsed Acute Lymphoblastic Leukemia (ALL) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695012) |
| June 26, 2026 | NCT07670260 | GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma | Chinese PLA General Hospital | Early phase 1 | Not yet recruiting | Relapsed or Refractory Large B-cell Lymphoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670260) |
| May 26, 2026 | NCT07606937 | A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma. | Shenzhen Fosun Kairos Biotechnology Co., Ltd. | Early phase 1 | Recruiting | Relapsed/Refractory Large B-cell Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07606937) |
| May 7, 2026 | NCT07574346 | IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies | Peking University People's Hospital | Early phase 1 | Recruiting | Malignancies | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07574346) |
| April 9, 2026 | NCT07519187 | CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms | The General Hospital of Western Theater Command | Early phase 1 | Recruiting | Relapsed or Refractory Plasma Cell Neoplasms | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519187) |
| February 12, 2026 | NCT07406178 | JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Relapsed/Refractory Pediatric B-ALL | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406178) |
| January 13, 2026 | NCT07337785 | CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | Tongji Hospital | Early phase 1 | Recruiting | Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07337785) |
| January 9, 2026 | NCT07330895 | Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors | The First Affiliated Hospital with Nanjing Medical University | Early phase 1 | Not yet recruiting | CD19+ Relapse/Refractory B-ALL | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07330895) |
| January 7, 2026 | NCT07322718 | Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases | Ruijin Hospital | Early phase 1 | Recruiting | Relapsed/Refractory B Cell-Mediated Autoimmune Diseases | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322718) |
| November 21, 2025 | NCT07241468 | An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory... | Changhai Hospital | Early phase 1 | Recruiting | Relapsed/Refractory Immune Nephropathy, Relapsed/Refractory Immune-mediated Kidney Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241468) |
| November 21, 2025 | NCT07240974 | Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | Relapsed/Refractory B-cell Malignancies | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240974) |
| November 18, 2025 | NCT07234721 | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Relapsed and Refractory Multiple Myeloma (RRMM) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234721) |
| July 22, 2025 | NCT07077330 | CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms | Chinese PLA General Hospital | Early phase 1 | Not yet recruiting | Relapsed or Refractory Plasma Cell Neoplasms | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077330) |
| May 31, 2025 | NCT06999031 | A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma | The First Affiliated Hospital of Nanchang University | Early phase 1 | Recruiting | Relapsed/Refractory, Multiple Myeloma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06999031) |
| May 23, 2025 | NCT06986434 | CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation | Affiliated Hospital to Academy of Military Medical Sciences | Early phase 1 | Not yet recruiting | Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06986434) |
| May 15, 2025 | NCT06972602 | High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed | Eye & ENT Hospital of Fudan University | Early phase 1 | Recruiting | Retinoblastoma, Retinoblastoma, Recurrent | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06972602) |
| February 20, 2025 | NCT06837389 | Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic... | The First Affiliated Hospital with Nanjing Medical University | Early phase 1 | Not yet recruiting | Relapsed or Refractory Hematological Malignancies | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06837389) |
| December 13, 2024 | NCT06732232 | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma | Shanghai Cell Therapy Group Co.,Ltd | Early phase 1 | Recruiting | Relapsed, Refractory, Multiple Myeloma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06732232) |
| December 12, 2024 | NCT06730256 | A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia | The First Affiliated Hospital of Soochow University | Early phase 1 | Recruiting | Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06730256) |
| December 5, 2024 | NCT06718270 | a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia | Shanghai Changzheng Hospital | Early phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06718270) |
| November 15, 2024 | NCT06691308 | WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Not yet recruiting | Recurrent or Progressive Glioblastoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06691308) |
| November 12, 2024 | NCT06684639 | A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma | The General Hospital of Western Theater Command | Early phase 1 | Recruiting | Neuroblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06684639) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Chinese PLA General Hospital | 2 |
| The Affiliated Hospital of Xuzhou Medical University | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| The General Hospital of Western Theater Command | 2 |
| Shanghai Changzheng Hospital | 1 |
| Ruijin Hospital | 1 |
| Peking University People's Hospital | 1 |
| Eye & ENT Hospital of Fudan University | 1 |
| Changhai Hospital | 1 |
| The First Affiliated Hospital of Nanchang University | 1 |
| Guangdong Second Provincial General Hospital | 1 |
| Zhujiang Hospital | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Tongji Hospital | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| Nationwide Children's Hospital | 1 |
| Shenzhen Fosun Kairos Biotechnology Co., Ltd. | 1 |
| Shanghai Cell Therapy Group Co.,Ltd | 1 |
| Affiliated Hospital to Academy of Military Medical Sciences | 1 |
| Peking University First Hospital | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| [Beijing Immunochina Medical Science & Technology Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-immunochina-medical-science-and-technology-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 22 |
| United States | 3 |
| Pakistan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Industrial cleaning companies in the United States](https://specstream.ai/data/businesses/industrial-cleaning-companies/united-states)
- [IT companies in the United States](https://specstream.ai/data/businesses/it-companies/united-states)
- [Latin American restaurants in the United States](https://specstream.ai/data/businesses/latin-american-restaurants/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Naturopathic clinics in the United States](https://specstream.ai/data/businesses/naturopathic-clinics/united-states)
